Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL.2, 2008, Pages 161-178

  Zwirska Korczala, Krystyna ^a   Sodowski, K ^a   Konturek, S J ^b   Kuka, D ^a   Kukla, M ^a   Brzozowski, T ^b   Cnota, W ^a   Wozniak Grygiel E ^a   Jaworek, J ^b   Buldak R ^a   Rybus Kalinowska, B ^a   Fryczkowski, M ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acylated ghrelin; Markers of inflammation; Meal; Polycystic ovary syndrome; Total ghrelin; Total PYY and PYY3 36

Indexed keywords

ADIPONECTIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GHRELIN; INSULIN; PEPTIDE YY; PEPTIDE YY [3-36]; VISFATIN;

ADULT; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONFERENCE PAPER; ENDOTHELIAL DYSFUNCTION; ENZYME IMMUNOASSAY; FEMALE; FOOD COMPOSITION; HUMAN; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; RADIOIMMUNOASSAY; RISK FACTOR; TEST MEAL;

ADIPONECTIN; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; GHRELIN; HUMANS; INFLAMMATION; INSULIN; OBESITY; PEPTIDE YY; POLYCYSTIC OVARY SYNDROME; POSTPRANDIAL PERIOD; RISK FACTORS; YOUNG ADULT;

EID: 51449117659     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Dasgupta S, Reddy BM. Present status of understanding on the genetic etiology of polycystic ovary syndrome. J Postgrad Med 2008; 54: 115-25.
2. Wannamethee SG. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. Int J Obes 2008; 32 (Suppl) 2: S25-S29.
3. Palmieri J. Implementing the National Cholesterol Education Program's update to the ATP III report. Manag Care Interface 2005; 18: 44-49.
4. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006; 116: 33-35.
5. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005; 90: 5711-5716.
6. Carmina E, Orio F, Palomba S et al. Endothelial dysfunction in PCOS: role of obesity and adipose tissue hormones. Am J Med 2006; 119(4): 356-363.
7. Bo S, Gambino R, Durazzo M et al. Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. J Endocrinol Invest 2008; 31: 499-504.
8. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
9. Escobar-Morreale, Villuendas G, Botella-Carretero JI et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006; 2257-2265.
10. Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747.
11. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome. Metab Clin Exp 2006; 55: 237-242.
12. Oktem M, Ebru Ozcimen E, Uckuyu A et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 2008; in press.
13. Vendrell J, Broch M, Vilarrasa N et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962-971.
14. Harsch IA, Bergmann T, Koebnick C et al. Adiponectin, resistin and subclinical inflammation - the metabolic burden in Launois Bensaude Syndrome, a rare form of obesity. J Physiol Pharmacol 2007; 58 (Suppl 1): 53-65.
15. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 21: 426-430.
16. Angelico F, Alessandri C, Ferro D et al. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-1174.
17. Zhang M, Yuan F, Chen H, Qiu X, Fang W. Effect of exogenous ghrelin on cell differentiation antigen CD40 expression in endothelial cells. Acta Biochim Biophys Sin 2007; 39: 974-981.
18. Gradin KA, Buus CL, Li Jy, Frobert O, Simonsen U. Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats. Br J Pharmacol 2006; 148: 703-713.
19. Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 2008; 143: 334-342.
20. Dixit VD, Schaffer EM, Pyle RS et. al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
21. Ukkola O, Pykk S, Pivnsalo M, Kesniemi A. Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis. Ann Med 2008; in press.
22. Zwirska-Korczala K, Konturek SJ, Sodowski K et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007; 58 (Suppl. 1): 13-35.
23. Ehrmann DA, Liljenquist DR, Kasza K et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 48-53.
24. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med 2008; 26: 39-44.
25. Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes 2005; 29 : 1452-1456.
26. Sodowski K, Zwirska-Korczala K, Kuka D et al. Basal and postprandial gut peptides affecting food intake in lean and obese pregnant women. J Physiol Pharmacol 2007; 58 (Suppl 1): 37-52.
27. Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005; 7: 2-5.
28. Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol 2008; 109: 242-246.
29. Tomizawa A, Hattori Y, Kasai K, Nakano Y. Adiponectin induces NF-kappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis Res 2008; 5: 123-127.
30. Glintborg D, Andersen M, Hagen C et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006; 155: 337-345.
31. Tarkun I, Berlin C, Zeynep A et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592-5596.
32. Orio F, Palomba S, Cascella T et al. Adiponectin levels in women with polycystic Ovary Syndrome. J Clin Endocrinol Metab 2003; 88: 2619-2623.
33. Kim SR, Bae YH, Bae SK et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-895.
34. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 2008; in press.
35. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007; 88: 401-405.
36. Kowalska I, Straczkowski M, Nikolajuk A et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007; 22: 1824-1829.
37. Sun G, Bishop J, Khalili S et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007; 85: 399-404.
38. Seow KM, Juan CC, Wu LY et al. Serum and adipocytes resistin in polycystic ovary syndrome. Hum Repr 2004; 19: 48-53.
39. Lu X, Huang H, Li M et al. Resistin levels of serum and follicular fluid in non-obese patients with polycystic ovary syndrome during IVF cycles. J Zhejiang Univ SCI 2005; 6B: 897-902.
40. Gauns C, Delhanty PJD, Ilofland LJ et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005; 90: 1055-1060.
41. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A prepandial rise in plasma ghrelin levels suggest a role in meal initiation in humans. Diabetes 2008; 50: 1714-1719.
42. Stock S, Leichner P, Wong AC et al. Ghrelin, peptide YY, glucose dependent insulinotropic polypeptide and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005; 90: 2126-2168.
43. Barber TM, Casanueva FF, Karpe F et al. Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158: 511-516.
44. Moran LJ, Noakes M, Clifton PM et al. Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. Am J Clin Nutr 2007; 86: 1603-1610.
45. Panidis D, Farmakiotis D, Koliakos G et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod 2005; 20: 2127-2132.
46. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschöp M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002; 87: 5625-5629.
47. Schöfl C, Horn R, Schill T et al. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4607-4610.
48. Gambineri A, Pagotto U, Tschöp M et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest 2003; 26: 629-634.
49. Parnell JA, Reimer RA. Differential secretion of satiety hormones with progression of obesity in JCR:LA-corpulent rats. Obesity 2008; 16: 736-742.
50. Boey D, Sainsbury A, Herzog H. The role of peptide YY in regulating glucose homeostasis. Peptides 2007; 28 : 390-395.
51. van den Hoek AM, Heijboer AC, Voshol PJ et al. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol 2007; 292 : E238-E245.
52. Tsilchorozidou T, Batterham RL, Conway GS. Metformin increases fasting plasma PYY in women with PCOS. Clin Endocrinol 2008; in press.